Who Paid My Doc
Ruth DO
Podiatrist San Diego, CA Doctor of Podiatric Medicine
NPI 1841687043 CMS profile 6220677
1809 National Ave, San Diego, CA 92113
General payments
$9,370
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Ruth DO of San Diego, CA is reported in the CMS Open Payments database as having received $9,370 across 149 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 91st percentile of Podiatrist profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $852 | 17 | |
| 2024 | General | $973 | 19 | |
| 2023 | General | $1,347 | 32 | |
| 2022 | General | $2,794 | 23 | |
| 2021 | General | $1,790 | 30 | |
| 2020 | General | $997 | 19 | |
| 2019 | General | $617 | 9 |
Beside peers
- Ruth DO
- Podiatrist median
- Middle half of Podiatrist
- National median
In program year 2025, general payments to Ruth DO were reported at $852. Among 4,572 Podiatrist profiles paid that year, the median was $260 and the middle half received between $94 and $777.
Show as a table
| Year | Ruth DO | Podiatrist median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $617 | $196 | $72–$601 | $163 |
| 2020 | $997 | $118 | $38–$335 | $114 |
| 2021 | $1,790 | $169 | $57–$573 | $132 |
| 2022 | $2,794 | $220 | $74–$782 | $149 |
| 2023 | $1,347 | $208 | $71–$635 | $160 |
| 2024 | $973 | $237 | $87–$681 | $164 |
| 2025 | $852 | $260 | $94–$777 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 7 drugsPart D claims
416
Drug cost
$5,266
Branded share of claims
3.4%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Clotrimazole | Generic | 133 | $2,116 | |
| Terbinafine Hcl | Generic | 126 | $1,348 | |
| Ammonium Lactate | Generic | 44 | $627 | |
| Gabapentin | Generic | 56 | $528 | |
| Diclofenac Sodium | Generic | 23 | $410 | |
| Nyamyc Nystatin | Brand | 14 | $168 | |
| Ibuprofen | Generic | 20 | $69 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.
Records
149 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Podiatrist in California
Related records
Podiatrist in California
Practitioners in the same specialty and state, ranked by reported value.
All Podiatrist
Everyone recorded under this specialty, nationwide.
Doctors in California
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.